DIA, Chicago 2017

Posted:

June 2017

Richmond Pharmacology is a frequent contributor and recognised thought leader for various scientific meetings worldwide.See below for updated list of upcoming events.

DIA (the Drug Information Association), 2017 18 - 22 June, 2017 | Chicago, USARichmond Pharmacology’s Principal Investigators Dr Taubel and Dr Lorch will be presenting at DIA 2017,ChicagoJoin our CEO Dr Jorg Taubel, who will be presenting on the topic ‘Combined Adaptive Early Phase Trials: From First-Time-in-Human to Proof of Concept in One Protocol’ Tuesday AM – 20th of June.Dr Ulrike Lorch will also be in attendance presenting ‘Combined Adaptive Early Phase Trials: From First-Time-in-Human to Proof of Concept in One Protocol’ her presentation will also take place Tuesday AM –20th June.For more information visit: DIA-2017

Back to news

More about us Adaptive Phase I, II & III Bridging Studies TQT Studies Patient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020

Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.

View event

COVID-19 – External Monitoring Guidelines

July 1, 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

First transdermal patch to treat schizophrenia hits market

March 18, 2020

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful

Statement: COVID-19

March 23, 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.